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In the last decades, the global epidemiological impact of invasive candidiasis (IC) in patients with 
hematologic malignancies (HM) and in hematopoietic stem cell transplant (HSCT) recipients ha
decreased and the incidence of invasive aspergillosis  exceeded that of Candida infections. The use 
of  prevention  strategies,  first  of  all  antifungal  prophylaxis  with  triazoles,    contributed  to  the 
reduction of IC in these populations as demonstrated by 
relatively  little  is  known  about  the  current  epidemiological  patterns  of  IC  in  HM  and  HSCT 
populations,  because  recent  epidemiological  data  almost  exclusively  derive  from  retrospective 
experiences and few prospective data are available. Several prospective, controlled studies in the 
prophylaxis of invasive fungal diseases have been conducted in both the HM and HSCT setting. On 
the  contrary,  most  of  the  prospective  controlled  trials  that  demonstrated  the  efficacy  of
antifungal  drugs  echinocandins  and  voriconazole  in  the  treatment  of  candidemia  and  invasive 
candidiasis mainly involved  patients with underlying conditions other than HM or  HSCT.  For 
these reasons, international guidelines provided specific indicat
HM  and  HSCT  patients,  whereas  the    recommendations  on  therapy  of  documented  Candida 
infections are based on the results observed in the general population and should be considered 
with caution.
Introduction: Invasive candidiasis (IC) is a major 
cause  of  morbidity  and  mortality  in  the  health  care 
setting.  Historically,  before  the  availability  of  azole
antifungal agents for  prophylaxis,  invasive infections 
caused  by  Candida  species  were  common  in  cancer 
patients, particularly in those affected by hematologic 
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In the last decades, the global epidemiological impact of invasive candidiasis (IC) in patients with 
hematologic malignancies (HM) and in hematopoietic stem cell transplant (HSCT) recipients ha
decreased and the incidence of invasive aspergillosis  exceeded that of Candida infections. The use 
of  prevention  strategies,  first  of  all  antifungal  prophylaxis  with  triazoles,    contributed  to  the 
reduction of IC in these populations as demonstrated by several  epidemiological studies. However, 
relatively  little  is  known  about  the  current  epidemiological  patterns  of  IC  in  HM  and  HSCT 
populations,  because  recent  epidemiological  data  almost  exclusively  derive  from  retrospective 
ive data are available. Several prospective, controlled studies in the 
prophylaxis of invasive fungal diseases have been conducted in both the HM and HSCT setting. On 
the  contrary,  most  of  the  prospective  controlled  trials  that  demonstrated  the  efficacy  of
antifungal  drugs  echinocandins  and  voriconazole  in  the  treatment  of  candidemia  and  invasive 
candidiasis mainly involved  patients with underlying conditions other than HM or  HSCT.  For 
these reasons, international guidelines provided specific indications for the prophylaxis strategies in 
HM  and  HSCT  patients,  whereas  the    recommendations  on  therapy  of  documented  Candida 
infections are based on the results observed in the general population and should be considered 
Invasive candidiasis (IC) is a major 
cause  of  morbidity  and  mortality  in  the  health  care 
setting.  Historically,  before  the  availability  of  azole
antifungal agents for  prophylaxis,  invasive infections 
species  were  common  in  cancer 
patients, particularly in those affected by hematologic 
malignancies  (HM),  and  in  hematopoietic  stem  cell 
transplantation  (HSCT)  recipients.
neutropenia related to the underlying malignancy and 
to  its  intensive  treatment  represented  the  main  risk 
factor for this and other IFDs. In the last decades, the 
overall  incidence  of  IC  has  significantly  increased 
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In the last decades, the global epidemiological impact of invasive candidiasis (IC) in patients with 
hematologic malignancies (HM) and in hematopoietic stem cell transplant (HSCT) recipients has 
decreased and the incidence of invasive aspergillosis  exceeded that of Candida infections. The use 
of  prevention  strategies,  first  of  all  antifungal  prophylaxis  with  triazoles,    contributed  to  the 
several  epidemiological studies. However, 
relatively  little  is  known  about  the  current  epidemiological  patterns  of  IC  in  HM  and  HSCT 
populations,  because  recent  epidemiological  data  almost  exclusively  derive  from  retrospective 
ive data are available. Several prospective, controlled studies in the 
prophylaxis of invasive fungal diseases have been conducted in both the HM and HSCT setting. On 
the  contrary,  most  of  the  prospective  controlled  trials  that  demonstrated  the  efficacy  of the 
antifungal  drugs  echinocandins  and  voriconazole  in  the  treatment  of  candidemia  and  invasive 
candidiasis mainly involved  patients with underlying conditions other than HM or  HSCT.  For 
ions for the prophylaxis strategies in 
HM  and  HSCT  patients,  whereas  the    recommendations  on  therapy  of  documented  Candida 
infections are based on the results observed in the general population and should be considered 
malignancies  (HM),  and  in  hematopoietic  stem  cell 
transplantation  (HSCT)  recipients.
1-9 Prolonged 
neutropenia related to the underlying malignancy and 
to  its  intensive  treatment  represented  the  main  risk 
factor for this and other IFDs. In the last decades, the 
overall  incidence  of  IC  has  significantly  increased Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
particularly  in  the  intensive  care  unit and  surgery 
settings as a consequence of the large use of invasive 
procedures,  intravenous  catheters,  and  intravenous 
hyperalimentation,  all  of  which  are  risk  factors  for 
candidemia  .  The  importance  of  these  procedures  as 
risk factors for candidemia has been observed also in 
HM  and  HSCT  patients,
10,11 however,  the  global 
epidemiological  impact  of  IC  in  such  populations 
decreased and the incidence of invasive aspergillosis 
(IA), exceeded that of Candida infections. The use of 
prevention strategies, first of all antifungal prophylaxis 
with  triazoles,   contributed  to  the  reduction of these 
infection in cancer patients as demonstrated by several  
epidemiological  studies.
9,12-14 On  the  other  hand  IC 
continues to be associated to a high mortality rate in 
these populations despite the introduction of additional 
antifungal agents.
15-17
IC  encompasses  a  large  variety  of  diseases  in 
immunocompromised  patients,  such  as  bloodstream 
infection,  chronic  hepatosplenic  candidiasis, 
endocarditis,  osteomyelitis,  endophthalmytis  and 
urinary tract infections, however, due to the difficulties 
in  diagnosing  invasive  infections  in  sites  other  than 
blood, conventionally epidemiological and therapeutic 
studies on IC almost exclusively include patients with 
candidemia. 
Herein,  we  will  summarize  epidemiological  and 
therapeutic aspects of candidemia in HM patients and 
HSCT recipients as reported in the literature of the last 
few  years  with  particular  attention  to  the  impact  of 
antifungal  prophylaxis  and  therapeutic  options with  
new antifungal drugs.
Epidemiology:  Relatively  little  is  known  about  the 
current  epidemiological  patterns  of  IC  in  HM  and 
HSCT populations. Despite an increasing attention to 
the  clinical and therapeutic aspects of candidemia in 
the heath care setting, there are few recent large studies 
on  the  incidence,  microbiologic  characteristics, 
resistance patterns, and clinical outcome  of  this  IFD 
focused on such populations. Recent epidemiological 
data  almost  exclusively  derive  from  retrospective 
experiences  and  few  prospective  data  are 
available.
13,14,18-24
A  nationwide  inpatient  data  base  for  adult  and 
pediatric patients in the United States showed that in 
2000 candidemia was diagnosed in an estimated 1118 
hospital  admissions  of  pediatric  patients  and  8949 
hospital  admissions  of  adult  patients.
18 Leukemia  or 
lymphoma  was  the  underling  condition  in  8%  of 
pediatric patients and 4 % of adult patients. HSCT was 
the inpatient procedure in 2% of pediatric patients and 
0.4% of adult patients.
Very recent clinical data from a general population 
of  patients with candidemia were extracted from the 
Prospective  Antifungal  Therapy  (PATH)  Alliance 
database,  a  comprehensive  North  American  registry 
that  collects  information  regarding  IFDs.
19
Contemporary  epidemiology  and  outcomes  of 
candidemia in multiple centers was evaluated in a total 
of  2019  patients,  enrolled  from  2004  through  2008. 
Data regarding the candidemia episodes were analyzed, 
including  the  specific  fungal  species  and  patient 
survival at 12 weeks after diagnosis. Overall, general 
medicine  (66%),  surgical  non-transplant  (33%)  and 
solid  tumours  (17%)  were  the  populations  more 
represented whereas 9.8% and 2.9% of the candidemia 
episodes were documented in patients with HM and in 
HSCT  recipients, respectively. Non-albicans  Candida 
species  accounted  for  the  large  majority  of  isolates 
(72.6% in HM and 77.6% in HSCT). This important 
study  on  candidemia  unfortunately  does  not  offer 
specific information on prognostic factors, antifungal 
therapy  and  outcome  in  patients  with  HM  but  in  a 
further  paper  some  data  on  HSCT  recipients  were 
specifically analyzed.
20
All these large surveys are able to show that HM 
and  HSCT  no  more  represent  the  most  frequent 
underlying  conditions  in  patients  with  candidemia. 
However,  these  experiences  were  not  primarily 
designed to evaluate risk and prognostic factors of IC 
in subgroups of patients such as those affected by HM 
or submitted to HSCT. 
Epidemiology  in  non  transplant  patients  with 
haematological  malignancies:  No  prospective 
multicenter  studies  and  only  few  retrospective 
experiences  on  IFDs  in  non  transplant  patients  with 
HM have been published in the last years. Herein, we 
will summarize the data derived from 3 recent large 
studies focused in the epidemiology of IC in the HM 
setting.
14,21,22
The largest epidemiological data on IFDs, including 
IC, in patients with HM derive from a retrospective, 
muticenter  study  from  Italian  hematologic  centers 
published  in  2004.
21 The  survey  was  conducted 
between January 1999 and December 2003, before the 
introduction  of  the  new  triazoles  (voriconazole  and 
posaconazole)  and  echinocandins  (caspofungin, 
micafungin  and  anidulafungin).  During  the  study 
period,  11,802  patients  with  newly  diagnosed 
hematologic  malignancies  were  admitted  to  18 
participating  centers  for  treatment  other  than  HSCT. 
The  overall  incidence  of  IFD  was  4.6%  and  the 
incidence of IC accounted for only 1.5% of patients. 
The diagnosis was based on blood cultures in all cases. 
More  than  80%  of  cases  of  Candida  infection  were 
documented in patients with acute leukaemia and the 
incidence  in  these  patients  accounted  for  3.5%.  The 
attributable mortality rate was 33% and ranged from Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
19%  in  non  Hodgkin  lymphoma    to  36%  in  acute 
lymphoid  leukemia.  Species-specific  attributable 
mortality rate ranged from 6% for infections caused by 
C. parapsilosis to 54% for those due to C. tropicalis.
Important  epidemiological  data  on  IFD  in  cancer 
patients  historically  derive  from  the  University  of 
Texas  MD  Anderson  Cancer  Center  (MDACC)  .  A 
retrospective,  study  of  candidemia  in  unselected 
hematologic  cancer  and  HSCT  patients.has  been 
conducted at  that institution  during the  period 2001-
2007.
22 The relevance of this study is also related to the 
introduction  of  new  antifungal  agents  such  as 
echinocandins  and  voriconazole  during  that  time. 
Overall 173 episodes of candidemia were detected in 
170  patients  with  HM. The  incidence  of candidemia 
per  100,000  inpatient  days  increased  from  13.9 
episodes  in  2001  to  23.2  in  2004,  although  a  slight 
decrease was observed during the last 2 years of the 
study (19.2 in 2006). These rates are higher than those 
reported  from  multi-institutional  European  surveys 
(0.26 to 0.73 per 10,000 inpatient days)
25,26 and United 
States-based surveillance studies (1.5 cases per 10,000 
inpatient  days).
27 Probably  the  higher  incidence 
observed at the MDACC may be justified by the high 
immunosuppression  in  their  population  and  by  the 
particular  attention  of  such  institution  in  the 
epidemiological  control  of  infectious  complications. 
Most  patients  (72%)  developed  breakthrough 
candidemia  while  receiving  antifungal  agents  in 
prophylaxis or treatment of other IFDs. Most infections 
(76%) were caused by non-albicans Candida species.  
The shift in the distribution of candidemia-associated 
Candida  species  to  non-albicans  species  has  been 
generally  attributed  to  the  widespread  use  of 
fluconazole,  however,  in  this  study,  only  29%  of 
patients were receiving fluconazole or itraconazole at 
the  onset  of  candidemia  therefore  the  non-albicans 
Candida spp. did not seem to be secondary to the use of 
triazoles  prophylaxis.  Furthermore,  in  vitro 
susceptibility pattern of Candida isolates in this study 
demonstrated  a  stable  susceptibility  to  triazoles 
compared to  previous periods at  the  same center,  in
fact  the  cumulative  rate  of  resistance  and  dose-
dependent  susceptibility  to  triazoles  was  29%  for 
fluconazole and 52% for itraconazole. Again, In vitro 
resistance  to  amphotericin  B  and  to  the  antifungal 
agents introduced into clinical practice after 2000 was 
uncommon. In fact,  only 4%,8%, 6%, and 5% of the 
isolates  exhibited  MIC  values  >  1  mg/L  with 
amphotericin  B,  voriconazole,  posaconazole,  and 
caspofungin.  
Crude  and  attributable  mortality  rates  have 
remained persistently high despite the introduction of 
new antifungal agents, and similar to those reported in 
older  studies  in  haematological  patients  with 
candidemia.  At  day  30  after  the  documentation  of 
candidemia, the overall mortality rate and attributable 
mortality rate was 38% and 19%, respectively. Most of 
deaths (84%) attributed to candidemia occurred by Day 
14.  The  Candida species associated  with  the  highest 
crude mortality rates at day 30 was C. glabrata (55%), 
followed by C. krusei (50%) and C.albicans (40%). A 
multivariate analysis showed that a high fungal burden, 
measured  by  quantitative  blood  cultures  in  the 
peripheral  blood,  and  delay  or  lack  of  neutrophil 
recovery were independent predictors of a high early 
mortality  rate.  Consistent  with  a  previous  study  in 
cancer patients that showed that catheter removal <72 
hours  after  onset  improved  response  to  antifungal 
therapy  in  patients  with  CVC  related  candidemia,
28
CVC removal within 3 days had a positive effect on 
early mortality rates. 
The authors concluded that the introduction of new 
antifungal agents and reduction of fluconazole use into 
clinical practice at their institution did not reduce the 
incidence of candidemia or the predominance of non-
albicans  Candida  spp.  among  patients  with  HM. 
Furthermore,  the  use  of  newer  antifungal  treatments 
and association therapies did not reduce the overall and 
Candida-attributable  mortality  rates.  Probably,  the 
underlying  hematologic  malignancy,  severity  of 
immunosuppression,  and  presence  of  indwelling 
devices represent determinant factors for the outcome 
more than any antifungal therapy. 
A contemporary, nationwide study of candidaemia 
was  conducted  in  Australia  over  a  3  year  period 
(August 2001–July 2004) by a prospective surveillance 
at public and private microbiology laboratories.
14 Out 
of  1095  incident cases  of  candidemia,  138  (12.6%) 
occurred in adults with HM .  The aims of this study 
were  to  determine  the  clinical  risk  factors  for 
candidemia  due  to    fluconazole-resistant  isolates  at 
presentation,  and  to  evaluate  whether  bloodstream 
infection with fluconazole-resistant Candida adversely 
affects  clinical  outcome  and/or  is  associated  with 
cross-resistance to other triazoles. C.albicans was the 
most  common  species  (32.7%)  followed  by 
C.parapsilosis  (19.5%),  C.krusei  (16.6%),  and 
C.glabrata (12.3%). No C.albicans and C.tropicalis and 
only  one  C.parapsilosis  isolate  was  resistant  to 
fluconazole.  Almost  all  C.glabrata  and  C.krusei 
isolates were resistant or susceptible-dose -dependent 
to  fluconazole  (MIC  >  8  mg/L).  By multivariate 
analysis, triazole therapy, gastrointestinal tract  surgery 
in the 30 days before candidaemia and age >65 years 
were  predictive  of  fluconazole-resistant  candidaemia. 
Thirty  day  crude  mortality  was  40%.  Fluconazole-
resistant isolates were associated with increased risk of 
mortality  by univariate  and  Kaplan–Meier  survival 
analyses. Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
Epidemiology  in  HSCT  recipients:  For  several 
decades, the most relevant epidemiological and clinical 
data  on  IFDs  in  the  HSCT  setting  derived  from the 
studies of the Fred Hutchinson Cancer Research Center 
(FHCRC)    of  Seattle.  Although  these  data  may  not 
reflect the current epidemiology of Candida infections 
in the transplant setting they continue to be of great 
value.  A retrospective study on patients  undergoing 
allogeneic HSCT from January 1994 to June 1997, all 
submitted to prophylaxis with fluconazole, showed that 
44% of patients were colonized by Candida but only 
4.6%  of  patients  developed  candidemia  with  a 
candidemia-associated  mortality  rate  of  20%...
13 C. 
albicans  was  the  most  common  pretransplant 
colonizing isolate, whereas resistant species such as C. 
krusei and C. glabrata were most commonly isolated 
after transplantation and exposure to fluconazole. Most 
of  strains  isolated  from  blood  were  resistant  to 
fluconazole,  including  2  C.albicans isolates  which 
accounted for  only 7% of cases  of candidemia.  It is 
likely  that  fluconazole  administration  decreased 
colonization  with  azole-susceptible  organisms, 
allowing  resistant  organisms  to  emerge.  This  study 
seems to show that antifungal prophylaxis is associated 
to  low  incidence  of  candidemia  and  attributable 
mortality  in  HSCT  recipients  despite  the  emerging 
phenomenon  of  colonization  and  infection  by 
fluconazole resistant strains. 
In the last few years, some multicenter studies on 
IFD  in  HSCT  recipients  have  been  reported  from 
Europe and North America and the main results, with a 
particular  focus  on  Candida  infections,  are  herein 
summarized.
20,23,24
A retrospective survey conducted in 11 tertiary care 
centers or university hospitals in  Italy between 1999 
and  2003  assessed  the  incidence  of  IFD  in  1979 
patients  submitted  to  autologous  HSCT  and  1249 
patients  submitted  to  allogeneic  HSCT.  Overall,  the 
incidence of IC was 1.1% and 0.8% in the allogeneic 
and  autologous  transplant  setting,  respectively.  C.
albicans was the etiologic agent in 43% of cases and 
non-albicans species of Candida were responsible for 
the other 57% of cases. Among non-albicans species of 
Candida,  C.glabrata,  C.krusei  and  C.guilliermondii
were the most frequently encountered. IC represented 
the  most  frequent  IFD  in  autologous  HSCT,  a 
condition  rarely  complicated  by  filamentous  fungi 
infections,  whereas in allogeneic  HSCT IA was the 
most  frequent  IFD  (incidence  6.3%).  This  large 
retrospective study showed a low incidence of IC in 
HSCT  patients;  the  overall  rate  of  mortality  due  to 
Candida  infection  was  0.5%  but  the  attributable 
mortality rate was 44%.  No difference in attributable 
mortality  rate  emerged  among  the  two  transplant 
procedures. Outcome was poorer among patients with 
infections  due  to  non-albicans  Candida  strains  than 
among  those  with  C.albicans  infection,  although  the 
difference was not significant (50% vs. 33%; P=0.5).
The Transplant Associated Infections Surveillance 
Network,  a  network  of  23  US  transplant  centers, 
prospectively  enrolled  HSCT  recipients  with  proven 
and probable IFIs occurring between March 2001 and 
March  2006.
24 The  denominator  data  on  all  HSCTs 
performed  and  clinical,  diagnostic,  and  outcome 
information for each IFD case were collected. Out of 
983 IFDs among 875 HSCT recipients 28% were IC. 
Among  276  patients  with  invasive  candidiasis,  C. 
glabrata  was  the  most  common  organism  (33%), 
followed by C. albicans (20%).  Median onset of IC 
after HSCT was 61 days. Within a cohort of 15,820 
incidence  patients  for  whom  follow-up  data  were 
available  the overall  12-month cumulative incidence 
of IFDs was  3.4%.  In particular the 6-month and 12-
month  cumulative  incidences  for  IC  were  1.0%  and 
1.1%, respectively. Overall, one year survival among 
HSCT patients with IC was 33.6%. No specific data 
are  available  in  this  study  regarding  the  cumulative 
incidence and survival stratified according to type of 
transplant.  This  study  seems  to  confirm  other 
experiences that IC, a relatively common IFD among 
this  patient  population  during  the  1980s  and  early 
1990s, now represents a minority  of IFDs and  non-
albicans Candida species accounts for almost most of 
these infections. Widespread use of azole prophylaxis 
has likely influenced the decreased incidence and shift 
in epidemiology in the HSCT setting , although other 
factors may play a role.
As  above  mentioned,  with  use  of  data  from  the 
North  American  PATH  Alliance  registry  which 
collected  information  regarding  IFDs,  a  multicenter, 
prospective,  observational  study  to  assess  the 
epidemiologic  characters  and  outcomes  of  IFD  was 
performed  in  HSCT  recipients.
20 Sixteen  medical
centers  reported  data  on  adult  HSCT recipients with 
proven or probable IFD during the period July 2004
through  September  2007.  Out  of  250  proven  or 
probable IFDs, documented in 234 patients submitted 
to allogeneic (161 patients) or autologous (73 patients) 
HSCT,  Candida  species  caused  25%  of  the  IFDs  in 
both HSCT populations. Overall, non-albicans Candida 
species  accounted  for  75.8%  of  the  isolates  and 
C.glabrata was the most common specie (43.5%) with 
a  similar  impact  in  the  allogeneic  (46.5%)  and
autologous  (36.8%)  transplant  setting.  Four  cases 
(11.3%)  were  due  to  C.krusei.  The  median  interval
between  HSCT and  diagnosis  of  IC  was  28  days  in 
autologous HSCT recipients and 108 days in allogeneic
HSCT recipients. Allogeneic transplant recipients who 
received  a  myeloablative  conditioning  regimen  wereMediterr J Hematol Infect Dis 2011; 3: Open Journal System
Table 1. Recent controlled studies of antifungal prophylaxis in patients with HM and HSCT recipients: efficacy in the prevention of invasive 
candidiasis.
Author, year of 
publication 
(reference n. )
Population Antifungal drugs Incidence of invasive 
Candida infections
Cornely, 2007 (34) Neutropenic patients with acute myeloid 
leukemia and myelodisplasticsyndromes
Posaconazole vs  fluconazole or 
itraconazole 3/304(1%)  vs 2/298 (0.7%)
van Buric,2004 (35) Allogeneic HSCT recipients until 
engraftment or day 42 post transplant Micafungin vs fluconazole 4/425(0.9%) vs  2/457(0.4%)
Ullmann, 2007 (36) Allogeneic HSCT recipients with graft 
versus host disease Posaconazole vs fluconazole 4/301(1.3%)  vs 4/299(1.3%)
Wingard, 2010 (37) Allogeneic HSCT recipients until day  100 
or 180 post transplant Voriconazole vs fluconazole 3/305 (1%)  vs 3/295 (1%)
more  likely  to  receive  a  diagnosis  of  IC  early  after 
HSCT (median interval, 65 days), compared with those 
who  received  a  nonmyeloablative  conditioning 
regimen (median interval, 590 days). Most of patients 
with  IC  were  treated  with  caspofungin  (52.6%) 
whereas 35% and 31.6% of patients received a  lipid 
formulation  of  amphotericin  B  and  fluconazole, 
respectively. The majority of HSCT recipients with IC 
(67.7%)  were reported to have responded (completely 
or partially) to the administered therapy. The 12-week 
mortality rate in patients with IC was 48.9%, higher 
than  that  observed in  patients  with  IA  (35.5%).  The 
true  attributable  mortality  rate  was    unclear  in  this 
registry. Because of the small number of patients with 
IC in this study, the authors were not able to obtain 
data on potential risk factors associated with mortality 
in HSCT recipients with IC
Current  Therapeutic  Options  of  Invasive 
Candidiasis in HM and HSCT Patients: In the last 
years,  several  prospective,  controlled  studies  in  the 
prophylaxis of IFDs have been conducted in both the 
HM and HSCT setting. On the contrary, most of the 
prospective  controlled trials  that  demonstrated  the 
efficacy  of  antifungal  drugs  in  the  treatment  of 
candidemia  and  invasive  candidiasis  focused  on 
nonneutropenic patients not affected by an HM.  For 
these  reasons,  international  guidelines  give  specific 
indications for  the  prophylaxis  strategies in  HM and 
HSCT  patients,  whereas  the    recommendations  on 
therapy of documented infections based on the results 
observed  in  the  general  population  should  be 
considered with caution.
Prophylaxis: Prevention strategies for IFD in HM and 
HSCT patients are based on environmental precautions 
and  antimicrobial  prophylaxis.  Although  there  is 
general  agreement  with  respect  to  the  environmental 
precautions, the role of pharmacological prophylaxis is 
still debated. Until few years ago fluconazole, and to a 
less  extent  itraconazole,  were  recommended  for 
primary  prophylaxis against  Candida  infection  in 
neutropenic patients and allogeneic HSCT recipients.
29-
33 This  prophylactic  strategy  proved  to  decrease  the 
rate of Candida infection and, in the transplant setting, 
was associated with an overall survival benefit at long-
term  follow-up.
31 However,  a  major  limitation  of  a 
Candida oriented  prophylaxis  is  the  lack  of  activity 
against  moulds  which  represent  the  most frequent 
cause  of  IFDs  in  such  populations.  In  the  past  few 
years,  several  broad  spectrum  antifungal  drugs  have 
been randomly compared with standard fluconazole for 
the prophylaxis of IFD in acute leukaemia and HSCT, 
with  the  aim  to  prevent  both  Candida  and  mould 
infections. The data of recent, large, randomized trials 
of antifungal prophylaxis in HM and HSCT patients, 
with  particular attention to the  prevention of IC, are 
summarized  in  table  1.
34-37 The  new  drugs 
posaconazole, voriconazole and micafungin proved to 
be as effective as fluconazole in the prevention of IC in 
high risk patients with neutropenia or graft versus host 
disease. The rate of IC in these studies was particularly 
low and there was no significant emergence of triazole 
resistant Candida strains. 
According  to  the  results  of  the  above  studies, 
international  guidelines  consider  fluconazole  (400 
mg/d  i.v  or  p.o)  as  the  drug  of  choice  for  primary 
prophylaxis in allogeneic HSCT recipients in the early 
phases from transplant.
38-41 Posaconazole (200 mg/tid  
p.o),  which  is  as  effective  as  fluconazole  in  the 
prevention of Candida infections but more effective in 
the  prevention  of  mould  infections,  is  the  drug  of
choice in patients with severe GVHD. In patients with 
acute  myeloid  leukemia  undergoing  intensive 
chemotherapy  fluconazole  is  no  more  the  drug  of 
choice  but  posaconazole  is  now  recommended.  A
potential limitation of posaconazole is represented by 
the erratic oral absorption, especially in patients with 
chemotherapy  related  intestinal  mucositis,  intestinal 
GVHD and/or diarrhea. In this setting, monitoring of
drug levels during therapy should be considered. The
role of voriconazole in the transplant setting deserves
further  evaluation.  It  should  be  stressed  that  for  the
strict  prevention  of  Candida infection  no  newMediterr J Hematol Infect Dis 2011; 3: Open Journal System
Table 2. Recent controlled studies of therapy of invasive candidiasis. Data of the overall population and available data of patients with HM 
and HSCT recipients.
Author, year of 
publication 
(reference n. )
Antifungal drugs
Success rate at end of study drug 
administration  in  the overall 
population
Available data  in patients with HM 
and HSCT recipients
Mora-Duarte, 2002 
(42) Caspofungin vs amphotericin B 73% vs 62% Success rate in neutropenic patients:  
7/14 (50%) vs 4/10 (40%)
Betts, 2009 (43) Caspofungin 70/50 mg vs 
caspofungin 150 mg 71.6% vs 68.2% Success rate in neutropenic patients:  
2/6 (33%) vs 4/7 (57%)
Reboli, 2007 (44) Anidulafungin vs fluconazole 74% vs 56.8%
Total neutropenic patients: 3 vs 2  
cases
No specific evaluation of success rate
Kuse, 2007 (45) Micafungin vs liposomal 
amphotericin B 89.6% vs 89.5% Success rate in neutropenic patients: 
18/24 (75%) vs 12/15 (80%)
Pappas, 2007 (46) Micafungin 100 mg vs micafungin 
150 mg  vs caspofungin 50 mg 76.4% vs 71.4% vs 72.3%
Total neutropenic patients: 22 vs 17  
vs 11 cases
Total HSCT recipients:10 vs 4 vs 4 
patients
No specific evaluation of success rate
Kullberg, 2005 (47) Voriconazole vs amphotericin B 
followed by fluconazole 70%  vs 74% Neutropenic patients were excluded 
from the study
antifungal  drug  showed  any  advantage  compared  to 
fluconazole.
Therapy  of  invasive  candidiasis:  All  echinocandins 
(caspofungin,  micafungin  and  anidulafungin)  and 
voriconazole have been evaluated in controlled clinical 
trials in the treatment of candidemia.
42-47 The data of 
the overall population enrolled and specifically those 
of patients with HM and HSCT recipients are detailed 
in  Table  2.  All  new  antifungal  drugs  proved  to  be 
effective, in some cases more effective, as compared to 
fluconazole or formulations of amphotericin B in the 
treatment  of  candidemia.  Very  limited  evaluation  of 
efficacy  was  possible  in  the  few    patients  with 
neutropenia, HM or submitted to HSCT. 
In  view  of  these  data,  the  most  recent  invasive 
candidiasis  treatment  guidelines
38-40,48 provided 
recommendations  for  the  general  population  and 
extended some indication for neutropenic patients even 
in absence of specific evidence. Fluconazole (loading 
dose  of  800mg  [12  mg/kg], then  400  mg [6  mg/kg] 
daily)  is  considered  the  primary  treatment  for 
nonneutropenic  patients  with  mild-to-moderate 
candidemia  and  no  recent  azole  exposure.  An 
echinocandin  antifungal  is  recommended  as  primary 
therapy  for  nonneutropenic  and  neutropenic  patients 
with moderately severe or severe candidemia or those 
who have had recent azole exposure. Transition to oral 
fluconazole is appropriate once the patient is clinically 
stable  and  the  isolate  is  definitely  speciated  or 
susceptibility to fluconazole is confirmed. Fluconazole 
is a reasonable alternative to echinocandin therapy in 
neutropenic  patients  with  mild-to-moderate 
candidemia. 
Conclusions:  Invasive  Candida infections  no  more 
represent  a  major  complication  of  patients  with  HM 
submitted  to  intensive  chemotherapy  and  of  HSCT 
recipients.  All  retrospective  and  prospective  surveys 
and  clinical  trials  in  such  populations  seem  to 
demonstrate that a prophylaxis strategy with the first 
generation triazoles (fluconazole and itraconazole), the 
second  generation  triazoles  (posaconazole  and 
voriconazole)  and  the  echinocandins  (caspofungin, 
micafungin  and  anidulafungin)  are  effective  in  the 
prevention of IC. Fluconazole may be chosen as the 
drug  of  choice  considering  its  efficacy  and  the  high 
costs of the other antifungal drugs, but the emerging 
epidemiological and clinical impact of IA and of other 
filamentous fungi infections in these populations has 
led  to  prefer  broad spectrum,  mould  active  drugs  in 
several clinical settings. 
Although the incidence of IC appears to  be quite 
low in HM and HSCT patients its high mortality rate 
continues  to  be  a  crucial  problem  despite  the 
availability of new effective antifungal drugs. On the 
other  hand,  it  should  be  considered  that  the  poor 
outcome  of  patients  with  IC  most  likely  reflects  the 
underlying  compromised  immune  status  and  organ 
function of patients who develop Candida infection.
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